CROP Secures Provisional Licence for a California Retail, Smoking Lounge, and State-Wide Delivery Service in Cathedral City.
Momentum Public Relations
Press Release: June 21, 2019
CROP INFRASTRUCTURE CORP. (CSE: CROP) (OTC: CRXPF) (Frankfurt: 2FR) announced today that its Emerald Heights retail brand has secured a provisional licence for a retail, delivery, and smoking lounge in Cathedral City, California, to vertically integrate its California brands.
CROP has also retained a local real estate broker to find suitable locations to set up its Emerald Heights flagship location. A $30,000 USD deposit has been placed and the balance of $220,000 USD will be paid on final transfer of ownership of the license. CROP’s subsidiary will be able to run delivery routes in the Bay Area, Coachella Valley, and is currently seeking a Southern California distribution partner.
CROP’s California extraction partner has run the first batch of material for extraction from the 2018 harvest into THC distillate oil, this first run will be used to fill 30,000 vape cartridges and combined with inventoried flower prepare 200,000 Moonrock Cones. Additional inventoried organic flower will produce ~100,000 pre rolled joints. These products are intended to be sold in the first Emerald Heights store and have a total wholesale value of $2,860,000 USD if sold through the company’s distribution company and partners and if sold at the Emerald Heights location a total retail value of over $6,000,000 USD.
CROP CEO, Michael Yorke, stated: “Emerald Heights’ entry into retail markets in California will be highly beneficial for CROP. We and our partners are working diligently to achieve as much value through the supply chain as possible for stakeholders.”
About Emerald Heights
Emerald Heights brand is focused on the so-called Emerald Triangle cannabis growing area and is a true California brand offering a heightened retail experience for adult customers of all ages. Emerald Heights aims to provide only the highest quality, state-compliant, organically sourced products in a safe and professional environment. Emerald Heights pays particular care to customer relations with its knowledgeable staff.
About CROP
CROP is publicly listed company trading under symbol CROP.CSE. The company is focused on cannabis branding and real estate assets. CROP’s portfolio of projects includes cultivation properties in California, two in Washington State, a 1,000-acre Nevada cannabis farm, 2,115 acres of Hemp CBD farms, and a growing portfolio of common share equity in upcoming listings within the cannabis space.
CROP has developed a portfolio of assets including Canna Drink, a cannabis infused functional beverage line and 16 Cannabis brands.
Company Contact
Michael Yorke – CEO and Director
E-mail: info@cropcorp.com
Website: www.cropcorp.com
Phone: (604) 484-4206
- Published in Cannabis, CBD, CROP Infrastructure, Marijuana, News Home
Sirona Biochem Reports 2019 AGM Voting and CEO Update
Momentum Public Relations
Press Release: June 20, 2019
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona“) is pleased to announce the voting results from its Annual General Meeting of Shareholders (the “Meeting”), held in Vancouver, British Columbia on June 20, 2019. The total number of shares represented by shareholders present in person and by proxy at the meeting was 32,141,666 million representing 15.47% of Sirona’s issued and outstanding Common Shares.
All of the matters put forward before shareholders for consideration and approval as set out in the Company’s Management Information Circular dated 22nd of May, 2019, were approved by the requisite majority of votes cast at the Meeting. The details of the voting results for the election of directors are set out below:
Nominee |
# Votes for |
% Votes for |
Géraldine Deliencourt-Godefroy |
31,845,566 |
99.1 |
Howard Verrico |
31,595,566 |
98.3 |
Christopher Hopton |
31,595,566 |
98.3 |
Alex Marazzi |
31,595,566 |
98.3 |
Jason Tian |
Appointed director |
The shareholders also approved: (i) fixing of the number of directors of the Company at five; (ii) appointing MNP LLP, Chartered Accountants, as the Company’s auditor for the ensuing year and authorizing the directors to set the auditor’s remuneration; and (iii) confirming and approving the Company’s existing stock option plan.
The Company will file a report of voting results on all resolutions voted on at the Meeting on www.sedar.com shortly.
CEO AGM Update
Dear Shareholders,
I’d like to take this opportunity to thank you for the continued support of Sirona. It is of great satisfaction to have over 98% of votes cast to support the current management team. This has been an exciting breakthrough year and we are grateful that you have remained on board with us, sharing our successes of Sirona’s novel platform technology.
Rodan + Fields have completed extensive due diligence on TFC-1067. This included both the data package provided by Sirona as well as their independent research and analysis on the compound. Rodan + Fields, the No. 1 skincare brand in North America in terms of total sales, are now moving our novel skin lightener towards full commercialization. The anticipated definitive agreement with Rodan + Fields has enormous value to Sirona, far beyond North America.
It is particularly important for our European shareholders to understand that Rodan + Fields utilizes approximately 300,000 consultants to sell products. Their skincare starter kits are aimed at reducing the appearance of lines, dark spots, and acne in adult women. Rodan + Fields are a perfect fit for Sirona and vice versa. We are confident Rodan + Fields will deliver industry leading products incorporating Sirona’s skin lightener TFC-1067.
After the heavy lifting is done and while we work together with Rodan + Fields through the stages of commercialization, further partners for other sales channels and regions will beat a path to our door. The discussions with our potential TFC-1067 partner for China are also nearing completion.
We anticipate more exciting news from China as Wanbang’s management meets to approve the release of information. We are also in advanced discussions on a large new project with a global corporation that we hope to share with you in Q4/2019.
The current market capitalization for Sirona Biochem has increased substantially thanks to positive company developments as well as growing shareholder support. Sirona’s management has now decided to establish a shareholder rights plan (“Poison Pill”) and has asked our legal counsel to take the necessary steps to put this in place.
The adoption of the Poison Pill is intended to protect Sirona Biochem and its shareholders from the actions of third parties that the Board of Directors determines are not in the best interests of Sirona Biochem and its shareholders, and to enable all shareholders to realize the long-term value of their investment in Sirona Biochem.
The Board of Directors believes that the Poison Pill will ensure that the Board of Directors remains in the best position to discharge its fiduciary duties to Sirona Biochem and its shareholders. The Poison Pill is not intended to interfere with any sale, merger, tender or exchange offer, or other business combination approved by the Board of Directors. Nor does the Poison Pill prevent the Sirona Biochem Board of Directors from considering any offer that it deems to be in the best interest of Sirona Biochem’s shareholders.
We have exciting times ahead of us.
Sincerely,
Dr. Howard Verrico, CEO
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
SOURCE Sirona Biochem Corp.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2019/20/c1114.html
Contact:
For more information regarding this press release, please contact: Investor Enquiries: Jonathan Williams, Managing Director, Momentum PR, Phone: 1.450.332.6939, Email: jwilliams@momentumpr.com
- Published in Life Sciences, News Home, Sirona Biochem
North Bud Capital Acquires Shares and Warrants of North Bud Farms Inc.
Momentum Public Relations
Press Release: June 20, 2019
This news release is issued by North Bud Capital Holdings Ltd. (“North Bud Capital”) pursuant to the early warning requirements of National Instrument 62-104 and National Instrument 62-103 with respect to the acquisition by North Bud Capital of units of North Bud Farms Inc. (the “Issuer”).
On June 19, 2019, in connection with the closing of a non-brokered private placement of the Issuer, North Bud Capital purchased 3,333,333 units in the share capital of the Reporting Issuer, at a price of $0.30 per unit, for gross proceeds to the Issuer of $1,000,000 (the “Private Placement Transaction”). Each unit consists of one common share and one common share purchase warrant, with each warrant entitling the holder thereof to purchase one additional common share in the share capital of the Issuer, at an exercise price of $0.40, and expiring on June 19, 2021.
Prior to the Private Placement Transaction, North Bud Capital owned and controlled 7,084,500 common shares in the share capital of the Issuer, representing 12.75% of the issued and outstanding common shares of the Issuer.
As a result of the closing of Private Placement Transaction, North Bud Capital holds a total of 10,417,833 common shares of the Issuer, representing 17.49% of the issued and outstanding common shares of the Issuer, and assuming the exercise of the 3,333,333 warrants comprised in the units, will hold a total of 13,751,166 common shares, representing a total of 21.86% of the issued and outstanding common shares of the Issuer on a partially diluted basis.
Depending on economic or market conditions, or matters relating to the Issuer, North Bud Capital may in the future choose to either acquire additional securities of the Issuer or dispose of securities of the Issuer.
For further information, and to obtain a copy of the early warning report filed under applicable securities legislation in connection with the transactions described herein, please go to the Issuer’s profile on the SEDAR website at www.sedar.com, or contact Mr. Ryan Brown, CEO of North Bud Capital at 855-359-2475.
North Bud Capital Holdings Ltd.
38 Ch. Scott
Chelsea, Quebec
J9B 1R5
Crystal Lake Mining Becomes Largest Landholder Among Juniors in Broader Eskay Camp
Momentum Public Relations
Press Release: June 20, 2019
Crystal Lake Mining Corporation (TSXV: CLM) (OTC PINK: SIOCF) (FSE: SOG-FF) (“Crystal Lake” or the “Company“) is pleased to announce that it has expanded the size of its Newmont Lake Project by approximately 25% to 551 sq. km (55,100 hectares), making Crystal Lake the largest landholder among junior companies in Northwest British Columbia’s broader Eskay Camp as the 2019 exploration season ramps up.
Highlights:
- The newly-defined Chachi Corridor (see June 12, 2019 news release) has been expanded by the staking of “Chachi East”, 17.5 sq. km of prospective ground straddling the northeast boundary of the Newmont Lake Project;
- On the western side of the project, Crystal Lake has also staked the 74 sq. km “Ridge West” block which represents the possible southwesterly extension of the Burgundy Ridge discovery (see March 7, 2019, news release). A large new gossan zone is exposed on the Ridge West block within Stikine volcanics.
- All new ground (115 sq. km) was acquired by staking, including a series of non-adjoining claims separate from Chachi East and Ridge West totaling 23.3 sq. km.
Maurizio “Mars” Napoli, Crystal Lake’s VP Exploration, commented: “We have managed to gain control of the potential extensions of two large and prospective corridors on the Newmont Lake Property. Vectoring of soil anomalies into Chachi East and the numerous mineral occurrences on Ridge West add to an already impressive land package at the Newmont Lake Project.”
Updated Claims Map Showing Chachi East, Ridge West
Crystal Lake Mining Expands its Newmont Lake Property with the Chachi East and Ridge West Staked Claims
To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6406/45763_caa5ca73f4d56a96_001full.jpg
Qualified Person
The technical information in this news release has been reviewed and approved by Mr. Maurizio Napoli, P.Geo., a qualified person responsible for the scientific and technical information contained herein under National Instrument 43-101 standards.
About Crystal Lake Mining
Crystal Lake Mining is a Canadian-based junior exploration company focused on building shareholder value through high-grade discovery opportunities in British Columbia and Ontario. The Company has an option to earn a 100% interest in the Newmont Lake Project, now the largest land package among juniors in the broader Eskay region in the heart of Northwest B.C.’s Golden Triangle.
On Behalf of the Board of Directors,
CRYSTAL LAKE MINING CORP.
“Richard Savage”
President & CEO
Email: info@crystallakemining.com
For further information please contact:
MarketSmart Communications
Tel: +1 (604) 261-4466
Toll Free: +1 (877) 261-4466
Email: info@marketsmart.ca
Momentum Public Relations
Tel: +1 (514) 815-7473
Email: mark@momentumpr.com
- Published in Crystal Lake Mining, Mining, News Home
Sirona Biochem Signs Term Sheet for TFC-1067 with Skincare Industry Leader Rodan + Fields
Momentum Public Relations
Press Release: June 19, 2019
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona“) is pleased to announce that a non-binding term sheet has been signed with Rodan + Fields, LLC (Rodan + Fields) for the commercial sales of novel ingredient TFC-1067. This term sheet covers all material terms and conditions of a definitive agreement with San Francisco-based, industry leading, Rodan + Fields. The definitive agreement is expected to be signed in Q3/2019.
The term sheet stipulates Sirona will become a manufacturer and supplier of TFC-1067 for use by Rodan + Fields on a non-exclusive basis in its current markets (USA, Canada and Australia) as well as future regions. Sirona has initiated preparations for manufacturing TFC-1067 to be in place near term for anticipated product launches. In addition to revenue from the sale of TFC-1067, a fee will be paid by Rodan + Fields on signing of the definitive agreement followed by milestone fees paid for each product launched by Rodan + Fields that incorporates Sirona’s innovative skin lightening agent TFC-1067.
The term sheet incorporates establishing regular formal meetings between Sirona’s scientists at TFChem and the scientists at the research department of Rodan + Fields. Future commercial opportunities based on the platform technology of Sirona Biochem will be explored. This term sheet is the result of extensive due diligence by Rodan + Fields spanning more than one year. This agreement is fitting for both Rodan + Fields and Sirona because of a mutual desire to deliver premium consumer products that are safe and effective.
Founded by Stanford-trained dermatologists, Dr. Katie Rodan and Dr. Kathy Fields, Rodan + Fields was launched with the mission of giving consumers the best skin of their lives and bring dermatology-inspired skincare to everyone. With clinic-quality skincare Regimens and a powerful community of Independent Consultants, Rodan + Fields is the leading skincare brand in the United States and one of the fastest growing industry disruptors in beauty.
Rodan + Fields has been ranked the number one skincare brand in the U.S.1 and North America2 in 2018 by Euromonitor International Ltd. (“Euromonitor”), which publishes the world’s most comprehensive market research on the skincare industry. Rodan + Fields has received several other accolades from Euromonitor, including the number one premium acne brand in the US and Canada3and number one premium body care brand in North America in 20184.
“After many years of developing TFC-1067 with the support of the French government and European Union in the Cosmetic Valley, France, we are excited to partner with skincare industry leader Rodan + Fields”, reports Dr. Howard Verrico CEO of Sirona Biochem. “This marks an important milestone for Sirona Biochem. We highly value the successful due diligence of Rodan + Fields as further validation of our technology platform, in particular TFC-1067.”
“We are committed to providing our Consultant community and their consumers with products that feature cutting-edge technology that provide visible results. After an extensive search, we are pleased to partner with Sirona to leverage their new brightening agent in our products. With clinically proven effectiveness and an excellent safety profile, TFC-1067 will enable our products to improve the appearance of skin dullness, discoloration and uneven skin tone for a younger looking complexion. We look forward to leveraging this excellent new ingredient in future product lines and working together to bring more of our lifechanging skincare products to the market,” said Simon Craw, Senior Director R&D Business Development at Rodan + Fields.
1Source Euromonitor International Limited; Beauty and Personal Care 2019 Edition, retail value RSP terms; all channels, Skincare includes Sets & Kits. |
2Source Euromonitor International Limited; Beauty and Personal Care 2019 Edition, retail value RSP terms; all channels, Skin Care includes Sets and Kits; North America defined as Canada and the United States. |
3Source Euromonitor International Limited; Beauty and Personal Care 2019 Edition, retail value RSP terms; all channels; Premium Acne Treatments including Acne Treatments sold as part of Sets and Kits. |
4Source Euromonitor International Limited; Beauty and Personal Care 2019 Edition, retail value RSP terms; all channels, Premium Body Care includes Sets and Kits. |
About Rodan + Fields
Founded by Stanford-trained dermatologists Dr. Katie Rodan and Dr. Kathy Fields, Rodan + Fields was launched in 2002 with the mission of giving consumers the best skin of their lives. The brand is a result of the Doctors’ belief that healthy skin empowers people to feel confident. Born in the digital era and designed to directly reach consumers where they live and shop via mobile and social networks, Rodan + Fields is disrupting the industry with its regimen-based skincare and powerful Independent Consultant community.
For more information, please visit www.rodanandfields.com.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
SOURCE Sirona Biochem Corp.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2019/19/c8969.html
Contact:
regarding this press release, please contact: Investor Enquiries: Jonathan Williams, Managing Director, Momentum PR, Phone: 1.450.332.6939, Email: jwilliams@momentumpr.com; Corporate Enquiries: Dr. Howard Verrico, CEO, Chairman of the Board, Sirona Biochem Corp., Phone: 1.604.641.4466, Email: info@sironabiochem.com; Rodan+ Fields: Corporate Communications + PR, Email: corporatepr@rodanandfields.com
- Published in Business, Life Sciences, News Home, Sirona Biochem
North Bud Farms Signs Binding Letter of Intent to Acquire California Licensed Extraction Company Tanforan Ventures
Momentum Public Relations
Press Release: June 18, 2019
North Bud Farms Inc.(CSE: NBUD) (OTCQB: NOBDF) (“NORTHBUD” or the “Company”) is pleased to announce that effective June 15, 2019 it has entered into a binding letter of intent (“LOI”) to acquire all of the issued and outstanding securities of Tanforan Ventures LLC (“Tanforan”), a California-based licensed operator holding Category 7 extraction and distribution licenses, in a transaction valued at CAD$8.6 million.
Tanforan holds manufacturing and distribution licenses in the state of California and is in the final stages of completing its new Category 7 licensed extraction facility in Woodland, California.
“We are very excited to have the opportunity to secure additional infrastructure and talent as we continue to execute on our U.S. expansion plans,” said Ryan Brown, CEO of North Bud Farms. “This strategically located extraction facility will facilitate the transportation of crude extract derived from bio-mass grown at contract farms located in Northern California. Assuming the successful closing of the proposed transaction with Tanforan and our previously announced transaction with Eureka Vapor, we intend to further process the crude extract into a finished consumer product at Eureka Vapor’s manufacturing and distribution facility located in Los Angeles to service the Southern California market.”
Transaction Terms
The proposed transaction (the “Transaction”) is currently structured as a share purchase agreement whereby in exchange for the purchase of all of the securities of Tanforan, NORTHBUD will issue CAD$5 million in common shares (“Common Shares”) to the shareholders of Tanforan (the “Tanforan Shareholders”) with the price per Common Share to be determined based on a formula of the higher of (a) CAD$0.35 per Common Share and (b) the 30-day volume weighted average price (“VWAP”) calculated on the closing date (the “Closing Date”) of a definitive agreement in respect of the Transaction (the “Definitive Agreement”). NORTHBUD and Tanforan expect to enter into the Definitive Agreement by October 1, 2019.
In addition, Tanforan shareholders will be entitled to receive up to an additional CAD$3.6 million in Common Shares of NORTHBUD, on a pro rata basis, upon Tanforan achieving revenue of USD$11,700,000 from extraction contracts over a 12 month period following the closing of the Transaction. All of the foregoing revenue milestone Common Shares will have a deemed value equal to the consideration shares and will be subject to the same escrow period.
10% of the Common Shares to be issued pursuant to the Definitive Agreement will be issued to the Tanforan shareholders on the Closing Date, with the remainder of the Common Shares to be issued in equal tranches after six, twelve, eighteen, and twenty-four months from the Closing Date (the “Escrow Period”).
The Transaction is a significant acquisition, but will not result in a “Fundamental Change” pursuant to the policies of the CSE. NORTHBUD will be preparing the necessary corporate and securities filings in order to secure the required approvals for the Transaction.
NORTHBUD has agreed to pay $150,000 in broker/finder fees to arm’s length parties in connection with the closing of the Transaction.
The closing of the Transaction is conditional on Tanforan receiving its final Certificate of Occupancy from the city of Woodland, the receipt of all applicable permits as well as the receipt by the parties of applicable corporate and regulatory approvals including that of the CSE.
“The opportunity to acquire a state-of-the-art facility with an experienced operations team is an exciting prospect for NORTHBUD,” says Ryan Brown, CEO of NORTHBUD. “We believe that the combination of Tanforan’s facility and services combined with Eureka Vapor’s products and distribution will give NORTHBUD an excellent platform to capitalize on the California recreational cannabis market, considered to be the largest in North America.”
“The Tanforan team is excited to join forces with NORTHBUD and Eureka to capitalize on the largest consumer market in North America,” said Shannan Day, CEO of Tanforan Ventures. “Tanforan has extensive exclusive agreements with licensed Cannabis farms in Northern California and we look forward to working with NORTHBUD and Eureka to create high quality products for distribution in Southern California.”
While the proposed transactions involving Tanforan and Eureka Vapor are complementary, they are independent and the Company may ultimately proceed to close one, both or neither of the proposed transactions, depending on market conditions and regulatory requirements.
Update on Acquisition of Eureka Vapor
As previously announced in the Company’s press release dated May 15, 2019, NORTHBUD and Eureka Vapor LLC (“Eureka”) continue to work towards completing a definitive agreement whereby NORTHBUD is to acquire all of the issued and outstanding shares of Eureka and all of its subsidiaries. Based on projected timelines for the completion of the audit of Eureka’s financial statements, the companies expect to sign a definitive agreement in the third quarter of the 2019 calendar year.
Update on Financing
The Company expects to close a first tranche of its non-brokered private placement later this week. As previously announced on May 15, 2019, the private placement is for up to 13,333,333 units at a price of $0.30 per unit, for gross proceeds of up to $4 million. Each unit will be comprised of one common share of the Company and one common share purchase warrant. Each warrant will entitle the holder to acquire an additional share at a price of $0.40 for a period of 24 months from the closing date.
About Tanforan Ventures LLC.
Historically Tanforan’s business operated under the proposition 215 regulatory structure. As of January 2019, Tanforan successfully applied for and received a volatile extraction license under the California adult use regulations laws. Tanforan specializes in white label extraction services.
About North Bud Farms Inc.
North Bud Farms Inc., through its wholly owned subsidiary GrowPros MMP Inc., is pursuing a licence under The Cannabis Act. The Company is constructing a state-of-the-art purpose-built cannabis production facility located on 95 acres of Agricultural Land in Low, Quebec. North Bud Farms Inc. will be focused on Pharmaceutical and Food Grade cannabinoid production in preparation for the legalization of edibles and ingestible products scheduled for October 2019.
About Eureka Vapor LLC
Headquartered in Los Angeles, California, EUREKA Vapor was founded in 2011 and holds licenses in both California and Colorado. EUREKA Vapor’s multi state operation manufactures and sells a premium line of vaporizer cartridges, disposable vapor pens and proprietary vaporizer batteries designed to work with their highly sought-after CO2 extracted oil. Using their refined extraction processes and techniques developed over almost a decade of extracting, EUREKA Vapor is committed to providing the cleanest and safest natural oil cartridges in the industry. Long referred to as one of the leaders in the industry, EUREKA has one of the most loyal customer bases in the category which reflects their commitment to honesty and transparency above all else. EUREKA continually looks for innovative ways to improve and refine their product offerings in order to deliver the best, most consistent vaping experience in the industry.
For more information visit: www.northbud.com
Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward- looking statements including those relating to the entering into of the Definitive Agreement, closing of the Transaction and associated approvals, Tanforan’s ability to achieve milestones under the Definitive Agreement and associated Common Share issuances. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such risks and uncertainties include, among others, the risk factors included in North Bud Farms Inc.’s final long form prospectus dated August 21, 2018 which is available under the issuer’s SEDAR profile at www.sedar.com.
FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
North Bud Farms Inc.
Edward Miller
VP, IR & Communications
Office: (855) 628-3420 ext. 3
investors@northbud.com
Tetra Bio-Pharma’s Management Provides Corporate Update Ahead of Annual General Meeting
Momentum Public Relations
Press Release: June 18, 2019
- U.S. granted patent protection for ophthalmic use;
- U.S. granted patent protection for topical delivery, increased drug solubility and abuse deterrence;
- U.S. FDA provides positive response on painful dry eye development program;
- Panag completes a Phase 3 clinical trial for a topical pain reliever;
- Tetra completes four clinical trials;
- Serenityã trial to launch in USA and Canada; and
- Promised revenues to meet delivery targets.
OTTAWA, June 18, 2019 (GLOBE NEWSWIRE) — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V: TBP) (OTCQB: TBPMF), a bio-pharmaceutical company engaged in cannabinoid-derived drug discovery and development, is pleased to provide investors with an update on our research, regulatory and commercial activities. This market update covers Tetra and its subsidiaries, Panag and Tetra Natural Health (TNH).
Tetra has grown from a small biotech to a biopharma with an enviable drug pipeline covering ophthalmic, chronic pain and oncology. The Company has completed four clinical trials providing in-depth knowledge on the safety and pharmacokinetics (how drugs are absorbed in the body) as well as preliminary data on the efficacy of several THC-CBD combinations. The Corporation acquired a large base of patent protection through its acquisition of Panag Pharma, and by forming partnerships with Altus Formulations (Altus) and Crescita Therapeutics (Crescita).
“Tetra’s pipeline is focused on large markets that represent significant potential revenues,” said Dr. Guy Chamberland, CEO and CSO of Tetra. “Our focus on these large markets has not precluded us from actively seeking Orphan Drug Designations. Delivering on our research promises along with solid patent protection has seen our story resonate with U.S. based institutional investors.”
Patent Equity Developments
The Corporation acquired Panag for its expertise in drug development as well as its drug pipeline and intellectual property. “This acquisition is very exciting for Tetra because it positions the Corporation as a key player in the ophthalmic inflammation and pain markets with Panag’s U.S. granted patent (U.S. patent no. 9,765,386 issued on January 24, 2017 for Compositions and Methods for Treatment of Ocular Inflammation and/or Pain),” commented Dr. Chamberland. “Our Joint Venture with Altus brings us multiple U.S. granted patents that cover insoluble drug delivery as well as drug abuse deterrence. A strong regulatory strategy along with Panag’s and Altus’ patents provides Tetra with a solid base of protection to bring these innovative drugs to market.”
Revenues
The Corporation promised revenues at the last Annual General Meeting of shareholders and has delivered on its promise with the Hemp Energy Drink. We will update shareholders on this at the upcoming AGM. “Further, with the acquisition of Panag this revenue stream is expected to grow before the end of fiscal 2019 and should exceed the previously promised target,” said Dr. Chamberland. The Corporation entered into a Joint Venture with Crescita to leverage the Panag topical technology which Tetra intends on launching multiple products within the natural health market by the end of this fiscal year. Similarly, the Corporation will submit several over the counter (i.e., DIN) drug applications by the end of this fiscal year. Crescita is also supported with a granted patent protection (U.S. patent number 8,343,962). Dr. Chamberland further commented, “The topical product launches will become an important revenue stream as Tetra moves full speed ahead with its drug development activities.”
Last week Panag announced the completion of the randomized controlled Phase 3 trial (PANAG – 001) and Tetra is in commercial discussions to expand sales of AwayeÔ in Europe. Data from the Phase 3 trial will allow Tetra to support all dermatology product candidates with strong evidence for efficacy claims. Tetra will use Crescitas’ MMPE™ patented delivery technology to improve the permeability of the active ingredient and develop the next generation of topical products. The patented Crescita formulation technology is part of the strategy to create prescription or OTC drug products for patient care.
Tetra Bio-Pharma Clinical Trial Updates:
Caumz:
Tetra has been ramping up activities to complete the CAUMZ™ Phase 3 clinical trial, called SERENITY©. The primary endpoint is to improve Health Related Quality of Life (HrQOL) in advanced cancer patients suffering from pain. Tetra has already secured more than 20 clinical sites, with 10 based in the United States. Tetra continues to plan for marketing approval by late 2020. We expect to submit regulatory approval documents beginning in Q4 of 2019. CAUMZ™ is a cannabinoid-derived medicine using synthetic THC and CBD which will be delivered using a vaporizer called the Mighty Medic, an approved Class 2 Health Canada medical device. Tetra is already involved in several discussions with potential commercialization partners from around the world.
Tetra is also preparing to resume activities associated with its Phase 2 trial called REBORN© which is a Head to Head Efficacy Study assessing CAUMZ™ versus Fentanyl® to study the onset of action for breakthrough pain in cancer patients. Tetra has been relocating these clinical activities to the USA with the objective to secure a second indication for CAUMZ™ in breakthrough cancer pain by mid-2021. This will significantly increase CAUMZ™ sales in year two.
Tetra will also launch a Phase 2 trial in fibromyalgia in 2020 for its product candidate CAUMZ™ in neuropathic pain as it expands the medical indications for use in its marketing claims. If approved by regulatory agencies, this would significantly impact sales by tapping into large therapeutic areas with unmet needs.
“We have successfully approached large, highly reputed clinical sites in the USA, a development that will bring two major advantages to Tetra: global credibility for our trials and increased speed of enrollment,” commented Dr. Chamberland.
PPP002:
As reported in Autumn 2018, the U.S. FDA, during both a Type B and Type C meetings, gave the greenlight to Tetra’s New Drug Application (NDA) under 505(b)(2). Tetra intends to file a New Drug Application (NDA) to bring PPP002 Dronabinol AdVersa™ to market. The PPP002 product is based on IntelGenX’s proprietary delivery system which should significantly reduce side effects and improve symptoms for patients suffering from Chemotherapy Induced Nausea and Vomiting (CINV).
In Q4 of this year, Tetra will launch the OPIOSPARE© clinical trial that will document opioid usage when patients take PPP002. Tetra will then seek to expand the marketing claims associated with PPP002 in order to increase the patient pool for its product candidate. In the event the product is approved, sales will grow as the Corporation provides evidence of opioid reduction.
PANAG – Tetra Bio-Pharma Updates:
PPP003:
Panag expects to launch its Combined Phase 1&2 program in painful dry eye in Q4 2019. Panag will evaluate the safety and tolerability of the product candidate HU308, a non-controlled cannabinoid-derived medicine which is expected to provide significant pain relief. Non-controlled signifies that the product is not considered to be a narcotic. We have initiated discussions with potential commercialization partners for this product. In addition, Panag in partnership with a veterinary ophthalmologist will conduct a proof-of-concept Phase 2 clinical trial in domestic dogs with HU308. “What is particularly noteworthy is that the study will involve domestic pets and not laboratory animals with a goal of providing pet owners with an alternative ophthalmic pain medication,” stated Dr. Chamberland. As previously announced, Tetra intends to create a Business Unit in the lucrative veterinary health market.
PPP009:
Panag expects to launch its Combined Phase 1&2 program in uveitis, an inflammatory eye condition, by Q1 2020. Panag will evaluate the safety and tolerability of a cannabinoid formulation for the management of this condition. Patients with uveitis are largely dissatisfied with the current standard of care and represent a population with a huge unmet medical need.
Chronic Pain Product Candidates:
Panag is developing a medical food therapy, along with intellectual property, for the treatment of interstitial cystitis. The non-controlled status of the medicinal ingredient will allow Tetra to target global markets. Tetra plans to begin commercializing some of these products in 2020 while Panag continues the development of a prescription drug product for both humans and pets.
Dermatology Rx and OTC Product Candidates:
After completion of the Panag Pharma acquisition in May 2019, Tetra has accelerated its development of PPP004, a topical formulation of THC and CBD targeting the general neuropathic pain drug market. On the clinical side, Panag and Tetra have developed a protocol targeting pain and inflammation in patients suffering from general neuropathic pain and have engaged clinical sites capable of running the trial. In parallel, Tetra has made significant progress in manufacturing PPP004, including securing supplies of GMP active pharmaceutical ingredients (APIs; synthetic THC and CBD), sourcing and purchasing scalable manufacturing equipment at the Company’s manufacturing partner in Moncton, New Brunswick; and engaging formulation experts to refine the formulation of PPP004 to underpin the development of a robust line of topical products that will meet the rigorous quality requirements of pharmaceutical products. These clinical and quality/manufacturing activities have allowed Tetra to develop documentation in preparation for regulatory filing, which is projected to occur in late 2019.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada authorized, and FDA reviewed, clinical trials aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
About Panag Pharma
Panag Pharma Inc. is a Canadian based bio-tech company focused on the development of novel cannabinoid-based formulations for the treatment of pain and inflammation. Panag believes that pain relief should be safe, non-addictive and above all; effective. The Panag Pharma team of PhD scientists and medical doctors are among the world’s leading researchers and clinicians in pain treatment and management. They bring a combined experience of over 100 years in research and clinical care of people dealing with chronic pain and inflammatory conditions. Panag’s current pipeline of pain relief products include formulations for the topical application to the skin, the eye and other mucous membranes. Recently approved by Health Canada and currently undergoing clinical trials, Panag Pharma’s Topical A OTC provides a new approach to the treatment of chronic pain and inflammation.
- Published in News Home, Tetra Bio Pharma
New Hemp Energy Drink to be offered to consumers in cannabis accessory stores, vapes stores, and kiosks in Canada and the US
Momentum Public Relations
Press Release: June 18, 2019
Tetra Natural Health, a subsidiary of Tetra Bio-Pharma (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced that it has signed an exclusive agreement with Spyder Cannabis Inc. (TSX VENTURE: SPDR) (“Spyder”) to distribute the three flavors of its Hemp Energy Drink in cannabis accessory stores and vapes stores in Canada and the US. The drink is expected to be available to consumers in Spyder’s retail stores located in Scarborough, Woodbridge, Burlington, and shortly at the Niagara Falls and Pickering locations, which are expected to be opened early this summer. A launch event will be held during the Canada Day long weekend at the Niagara Falls location situated at 6474 Lundys Lane.
“We are very excited to be adding the Hemp Energy Drink to our portfolio of premium brands that will be available to our growing clientele,” stated Daniel Pelchovitz, CEO and President of Spyder. “This new offering will please our customers who are always seeking unique and distinctive quality products in this emerging industry.”
“This exclusive agreement allows us to take another step in implementing our distribution strategy and achieving our goal of making our Hemp Energy Drink accessible to all consumers “ said Richard Giguère, CEO of Tetra Natural Health “Consumers appreciate the qualities of the Hemp Energy Drink (HED) including the fact that it contains more natural ingredients than other energy drinks, and is the first energy drink made with hemp available in the country” adds Derek Theriault, National Sales Director of Tetra Natural Health.
About Tetra Natural Health:
Tetra Natural Health Inc. is a subsidiary of Tetra Bio-Pharma Inc. that focuses on identification, development and marketing of hemp or cannabis-based natural health products, or cannabinoids-based products authorized for sale by Health Canada. For more information, visit: www.tetranaturalhealth.com
About Spyder Cannabis Inc.
Founded in 2014 Spyder is an established chain of three high-end vape stores in Ontario, with stores located in Woodbridge, Scarborough and Burlington. The Spyder brand is defined by its high-quality proprietary line of e-juice, liquids and exclusive retail deals, dispensed in uniquely designed stores creating the optimal customer experience. Spyder is building off this leading retail, distribution and branding eCig and vapes company and is pursuing expansion into the legal cannabis market. Spyder has developed a scalable retail model with an aggressive expansion plan to create a significant retail footprint with targeted and disciplined retail distribution strategy focusing on Canadian locations in high traffic peripheral areas.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved and FDA reviewed clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Tetra Bio-Pharma has subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of its mission, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies. For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
More information at: www.tetrabiopharma.com
For more information, please contact:
Tetra Natural Health
Richard Giguère, CEO
Tel.: (348) 899-7575 ext. 210
rgiguere@tetranaturalhealth.com
Spyder Cannabis Inc.
Dan Pelchovitz, President and CEO
Tel: (905) 265-8273
dan@spydervapes.com
- Published in Cannabis, Marijuana, Medical Marijuana, News Home
Maurizio Napoli Joins Crystal Lake Mining’s Team as Vice-President of Exploration
Momentum Public Relations
Press Release: June 18, 2019
Crystal Lake Mining Corporation (TSXV: CLM) (OTC Pink: SIOCF) (FSE: SOG-FF) (“Crystal Lake” or the “Company“) is pleased to announce the appointment of Maurizio “Mars” Napoli as VP Exploration, effective immediately.
Mars Napoli is an accomplished professional geologist with over 33 years of experience in the mineral exploration business. He began his career studying gold mineralization in Northern Ontario with the Ministry of Northern Development and Mines. Subsequently he worked for 30 years with Inco Ltd. and Vale Canada in the Thompson and Sudbury nickel camps and with their North American and Global Exploration groups exploring for Archean greenstone gold, magmatic-hosted nickel-copper, uranium and porphyry-style copper systems.
“We searched hard for the right candidate and we’re thrilled to have Mars join our team as VP Exploration,” stated Richard Savage, Crystal Lake President and CEO. “His experience with high-grade gold systems and a broad array of other deposit types will help drive our success this summer with the Newmont Lake Project in the Eskay Camp.”
Napoli is an experienced exploration program manager from grassroots and brownfield exploration through to discovery and resource definition. He managed large exploration programs for Vale Canada and Sudbury Basin groups. The exploration teams Mars worked with enjoyed large world-class economic discoveries in Thompson, Sudbury and South America.
“Crystal Lake’s project has so many exciting components to it with multiple discovery opportunities given the historic data I’ve analyzed and the work we’ve already carried out,” stated Napoli. “I’m excited to be part of what I consider to be an exceptional team in the right area at the right time. With state-of-the-art exploration tools at our disposal, and such a prospective large land package, Crystal Lake has quickly become a key player in the Eskay district and the broader Golden Triangle.”
Napoli, who graduated with honours in 1983 and received his Master’s degree from Laurentian University in 2003, is a registered Professional Geologist with the Association of Professional Geologists of Ontario.
About Crystal Lake Mining
Crystal Lake Mining is a Canadian-based junior exploration company focused on building shareholder value through high-grade discovery opportunities in British Columbia and Ontario. The Company has an option to earn a 100% interest in the Newmont Lake Project, one of the largest land packages among juniors in the broader Eskay region in the heart of Northwest B.C.’s Golden Triangle.
On Behalf of the Board of Directors,
CRYSTAL LAKE MINING CORP.
“Richard Savage”
President & CEO
Email: info@crystallakemining.com
For further information please contact:
MarketSmart Communications
Tel: +1 (604) 261-4466
Toll Free: +1 (877) 261-4466
Email: info@marketsmart.ca
Momentum Public Relations
Tel: +1 (514) 815-7473
Email: mark@momentumpr.com
Maurizio Napoli Joins Crystal Lake Mining’s Team as Vice-President of Exploration
Cannot view this image? Visit:
https://orders.newsfilecorp.com/files/6406/45678_maurizio.jpg
- Published in Crystal Lake Mining, Mining, News Home